Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oxford BioMedica
There are two parts to the study. A dose-escalation phase looking at three doses of RetinoStat starting with the lowest dose, three patients will be recruited at each dose level. The escalation phase will be followed by a dose confirmation phase where the highest dose that is safe and well tolerated will be examined in 9 patients.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of AMD with active CNV that shows evidence of leakage.
BCVA less than or equal to 20/200 in the study eye for dose escalation phase.
BCVA less than or equal to 20/80 in the study eye for maximum tolerated dose phase.
You may not be if
Significant ocular abnormalities that prevent retinal assessment.
Treatment with steroids within three months of screening.
Treatment with anti-VEGF therapy to either eye within one month of screening.
Clinically significant intercurrent illnesses, laboratory, ECG or chest XRay abnormalities.
